A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study

Imagem de Miniatura
Arquivos
art_LOUZA_A_Multicenter_Open_Label_Trial_to_Evaluate_the_2013.PDF (650.48 KB)
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS INC
Autores
MATTOS, Paulo
PALMINI, Andre Luis Fernandes
OLIVEIRA, Irismar Reis de
ROCHA, Fabio Lopes
Citação
JOURNAL OF ATTENTION DISORDERS, v.17, n.5, p.444-448, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD. Objective: To assess the effectiveness of Methyphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. Method: A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted. Results: Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p < .0001), as well as the Total AAQoL (p < .0001). A significant reduction on Clinical Global Impression-Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p < .0001). No serious adverse event was reported. Conclusion: Treatment of adult ADHD patients with OROS MPH improves QoL.
Palavras-chave
ADHD, adult ADHD, stimulants
URI
https://observatorio.fm.usp.br/handle/OPI/2404
Referências
  1. Able SL, 2007, PSYCHOL MED, V37, P97, DOI 10.1017/S0033291706008713
  2. Adler LA, 2006, J CLIN PSYCHOPHARM, V26, P648, DOI 10.1097/01.jcp.0000239797.21826.70
  3. Am. Psychiatr. Assoc, 1994, DIAGNOSTIC AND STATI
  4. Brod M, 2006, QUAL LIFE RES, V15, P117, DOI 10.1007/s11136-005-8325-z
  5. Faraone SV, 2004, J CLIN PSYCHOPHARM, V24, P24, DOI 10.1097/01.jcp.0000108984.11879.95
  6. Gathje RA, 2008, J ATTEN DISORD, V11, P529, DOI 10.1177/1087054707314028
  7. GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619
  8. Goksoyr PK, 2008, ADDICT BEHAV, V33, P342, DOI 10.1016/j.addbeh.2007.09.008
  9. Goodman DW, 2005, CNS SPECTRUMS, V10, P26
  10. Grevet EH, 2005, ARQ NEURO-PSIQUIAT, V63, P307, DOI 10.1590/S0004-282X2005000200019
  11. Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716
  12. Knouse LE, 2008, J ATTEN DISORD, V11, P652, DOI 10.1177/1087054707299411
  13. Mattos P, 2011, REV PSIQ CLIN-BRAZIL, V38, P91, DOI 10.1590/S0101-60832011000300002
  14. Mattos Paulo, 2006, Rev. psiquiatr. clín., V33, P188, DOI 10.1590/S0101-60832006000400004
  15. Mattos P., 2006, REV PSIQUIATRIA RIO, V28, P50, DOI 10.1590/S0101-81082006000100007
  16. Mattos P, 2011, REV PSIQ CLIN-BRAZIL, V38, P87, DOI 10.1590/S0101-60832011000300001
  17. Szobot CM, 2008, BRAZ J MED BIOL RES, V41, P250, DOI 10.1590/S0100-879X2008005000011

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq